Search results | astrazeneca


Partnering Agreements with AstraZeneca

This report provides all the information you require to better understand AstraZeneca and its partnering interests and activities over the past seven years.


AstraZeneca and Pfizer in the news for another possible m&a bid

AstraZeneca stock rose two percent to £45.67 pounds yesterday after the Swedish newspaper Dagens Industry suggested another possible Pfizer m&a  bid. AstraZeneca stocks have risen 9.5% in the last week, following a stream of good news regarding its pipeline and takeover bids by Pfizer.


AstraZeneca is a top pharmaceutical company based in London, United Kingdom

Pfizer gives up on AstraZeneca

Pfizer has given up on its attempt to take over the British pharmaceutical company AstraZeneca.

AstraZeneca rejects Pfizer’s final offer, again

On Friday May 16th, 2014, Pfizer announces its final proposal to combine the two companies.

AstraZeneca rejects Pfizer’s takeover offer

The board of pharmaceutical company AstraZeneca on Friday flatly rejected drug maker Pfizer’s sweetened takeover offer just hours after it was levelled, describing it as inadequate.

Pfizer confirms its offer for AstraZeneca

Pfizer is close to publicly unveiling its interest in acquiring AstraZeneca of Britain, a person briefed on the matter said on Sunday, in what would be one of the biggest deals among drug makers.

Rumours swirl of Pfizer bid for AstraZeneca triggering M&A fever

The recently disclosed failed bid by Pfizer to acquire bigpharma rival AstraZeneca has analysts predicting several outcomes as M&A fever sweeps the pharma sector

AstraZeneca rumored to be pursuing Forest Laboratories

British drug maker AstraZeneca recently made an abortive acquisition approach to Forest Laboratories before the specialty-drug company agreed last week to be bought by Actavis for $25 billion, according to people familiar with the matter.

AstraZeneca is eyeing Forest Laboratories for acquisition

AstraZeneca (AZ) is considering a acquisition bid for Forest Laboratories of the US, according to a Financial Times report which cites people close to two companies.

AstraZeneca is speculated to buy diabetes JV from Bristol

AstraZeneca may seek to increase its stake in a diabetes joint venture with Bristol-Myers Squibb, following a decision by the U.S. firm to exit diabetes drug research.


Sorry, your search returned no results.


AstraZeneca and Innate Pharma in IPH2201 deal

Innate Pharma has signed a co-development and commercialization agreement with AstraZeneca

Celgene and AstraZeneca in MEDI4736 pact

Celgene has entered into a strategic collaboration with MedImmune to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies

AstraZeneca partners with PatientsLikeMe

PatientsLikeMe and AstraZeneca have signed a five-year agreement to provide access to PatientsLikeMe’s global network in support of AstraZeneca’s patient-driven research initiatives

AstraZeneca and Daiichi to co-promote Movantik

AstraZeneca announced a co-commercialisation agreement with Daiichi Sankyo for MOVANTIK (naloxegol)

AstraZeneca leads $40 million investment in PhaseBio

PhaseBio Pharmaceuticals has closed a $40 million Series C financing round led by AstraZeneca.

AstraZeneca to spin out antibiotics business

AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company

AstraZeneca and Orca Pharma in ROR gamma inhibitor pact

Orca Pharmaceuticals and AstraZeneca announced a three year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma

AstraZeneca enters asset purchase deal for branded respiratory portfolio

AstraZeneca and Actavis have entered into a definitive asset purchase agreement under which AstraZeneca will acquire the rights to Actavis’ branded respiratory business in the US and Canada for an initial consideration of

AstraZeneca establishes four CRISPR technology pacts

AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform

AstraZeneca partners with Molplex for mechanisms of cancer progression

Molplex Pharmaceuticals has announced a pioneering new research collaboration agreement with AstraZeneca